Jackson J M, Talbot S T, Lee H A
Department of Renal and Metabolic Medicine, University of Southampton, St. Mary's Hospital, Portsmouth, UK.
Clin Chim Acta. 1995 Jul 31;239(1):81-9. doi: 10.1016/0009-8981(95)06103-k.
We have inhibited the in vitro generation of non-esterified fatty acids in plasma samples taken during haemodialysis by cooling the samples rapidly, centrifuging and freezing within 5 min of sampling and completing the assay on the same day. The relationship of non-esterified fatty acid concentrations during haemodialysis to the acetate concentration of the dialysate and the profile of circulating lipase activities was studied. With this sample-handling protocol we found lower non-esterified fatty acid concentrations than reported in many other studies and the results suggest that, under normal conditions of haemodialysis, the circulating non-esterified fatty acid concentrations and the associated risk of unwanted side-effects may have been previously over-estimated due to artefactual in vitro sample lipolysis. We also showed that, at the end of dialysis, when circulating lipase activities were least, the non-esterified fatty acid concentrations were lower (P < 0.05) with an acetate dialysate containing 37 mmol/l acetate than with a bicarbonate dialysate containing 3 mmol/l acetate.
我们通过在采样后5分钟内迅速冷却样本、离心并冷冻,然后在同一天完成检测,抑制了血液透析期间采集的血浆样本中非酯化脂肪酸的体外生成。研究了血液透析期间非酯化脂肪酸浓度与透析液醋酸盐浓度以及循环脂肪酶活性谱之间的关系。采用这种样本处理方案,我们发现非酯化脂肪酸浓度比许多其他研究报告的要低,结果表明,在正常血液透析条件下,由于体外样本的人为脂解作用,循环中非酯化脂肪酸浓度以及相关的不良副作用风险可能先前被高估了。我们还表明,在透析结束时,当循环脂肪酶活性最低时,与含有3 mmol/L醋酸盐的碳酸氢盐透析液相比,含有37 mmol/L醋酸盐的醋酸盐透析液的非酯化脂肪酸浓度更低(P < 0.05)。